Resection of peritoneal implantation of hepatocellular carcinoma after hepatic resection: risk factors and prognostic analysis
- PMID: 14994148
- DOI: 10.1007/s00268-003-7319-7
Resection of peritoneal implantation of hepatocellular carcinoma after hepatic resection: risk factors and prognostic analysis
Abstract
Peritoneal implantation from hepatocellular carcinoma (HCC) after hepatic resection is infrequent, and information on risk factors and long-term survival of such patients is lacking. The clinicopathologic features and risk factors of 16 HCC patients after hepatic resection who developed peritoneal implantation from an HCC and the prognosis after surgical resection of these HCC implants were assessed. The clinical features of 16 HCC patients after hepatic resection undergoing resection of peritoneal HCC implants (P-HCC) from 1986 and 2000 were reviewed. The clinical features and outcomes of 195 HCC patients undergoing hepatectomy without recurrence (NR-HCC) were used for comparison. During 1986 and 2000 a total of 749 HCC patients underwent hepatic resection. Of these 749 patients, 465 (62.1%) had HCC recurrence after hepatic resection during the follow-up period (median 26 months). Of the 465 patients, 26 (5.6%) developed peritoneal implants, and 16 of them underwent resection. Multivariate logistic regression analysis revealed that a high alpha-fetoprotein (AFP) level and capsular invasion by the tumor cells may predispose posthepatectomy patients to peritoneal implantation from their HCCs. The overall survival of the P-HCC patients after peritoneal implant resection was similar to that of the NR-HCC patients. An elevated AFP level might be regarded as a significant prognostic factor for poor overall survival ( p = 0.0577) after resection of peritoneal implants from HCCs. Peritoneal implantation occurs infrequently in posthepatectomy patients with an HCC. Elevated AFP values and capsule invasion by tumor cells may predispose posthepatectomy patients to peritoneal implantation from HCCs. Surgical resection of peritoneal implants from HCCs may prolong survival in selected patients. Elevated AFP levels may be regarded as a possibly significant prognostic factor for poor overall survival after resection of peritoneal HCC implants.
Similar articles
-
Resection of peritoneal implantation from hepatocellular carcinoma.Ann Surg Oncol. 2002 Nov;9(9):863-8. doi: 10.1007/BF02557522. Ann Surg Oncol. 2002. PMID: 12417507
-
Long-term survival following resection of peritoneal implantation from hepatocellular carcinoma: a case report.Hepatogastroenterology. 2005 Jul-Aug;52(64):1221-3. Hepatogastroenterology. 2005. PMID: 16001666
-
Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution.Surgery. 2015 Apr;157(4):645-53. doi: 10.1016/j.surg.2014.07.024. Epub 2014 Nov 4. Surgery. 2015. PMID: 25794626
-
Aggressive multimodal treatment for peritoneal dissemination and needle tract implantation of hepatocellular carcinoma: a case report.Jpn J Clin Oncol. 2004 Sep;34(9):551-5. doi: 10.1093/jjco/hyh096. Jpn J Clin Oncol. 2004. PMID: 15466830 Review.
-
The prognostic significance of clinical and pathological features in hepatocellular carcinoma.World J Gastroenterol. 2002 Apr;8(2):193-9. doi: 10.3748/wjg.v8.i2.193. World J Gastroenterol. 2002. PMID: 11925590 Free PMC article. Review.
Cited by
-
Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma: review of 1222 cases of hepatectomy in a tertiary institution.Ann Surg Oncol. 2012 Jul;19(7):2246-55. doi: 10.1245/s10434-012-2260-3. Epub 2012 Mar 9. Ann Surg Oncol. 2012. PMID: 22402812 Free PMC article.
-
Laparoscopic liver resections for hepatocellular carcinoma. Is it a feasible option for patients with liver cirrhosis?Langenbecks Arch Surg. 2009 Mar;394(2):255-64. doi: 10.1007/s00423-008-0349-8. Epub 2008 Jun 14. Langenbecks Arch Surg. 2009. PMID: 18553101
-
A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment.J Liver Cancer. 2023 Mar;23(1):206-212. doi: 10.17998/jlc.2023.02.09. Epub 2023 Feb 24. J Liver Cancer. 2023. PMID: 37384027 Free PMC article.
-
Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients.Heliyon. 2023 Nov 1;9(11):e21906. doi: 10.1016/j.heliyon.2023.e21906. eCollection 2023 Nov. Heliyon. 2023. PMID: 38028013 Free PMC article.
-
A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes.Clin Exp Hepatol. 2022 Mar;8(1):42-48. doi: 10.5114/ceh.2022.114297. Epub 2022 Mar 23. Clin Exp Hepatol. 2022. PMID: 35415264 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical